Get the Stockscreener App
16.95
7.48%
-1.37
After Hours:
16.91
-0.04
-0.24%
Immunovant Inc stock is traded at $16.95, with a volume of 4.51M.
It is down -7.48% in the last 24 hours and up +7.62% over the past month.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
See More
Previous Close:
$18.32
Open:
$16.32
24h Volume:
4.51M
Relative Volume:
3.56
Market Cap:
$2.90B
Revenue:
-
Net Income/Loss:
$-382.71M
P/E Ratio:
-6.4695
EPS:
-2.62
Net Cash Flow:
$-325.64M
1W Performance:
-5.36%
1M Performance:
+7.62%
6M Performance:
-26.46%
1Y Performance:
-39.03%
1-Day Range:
$15.31
$17.31
1-Week Range:
$15.31
$18.64
52-Week Range:
$12.72
$34.47
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-580-3099
Address
320 WEST 37TH STREET, NEW YORK, NY
Compare IMVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
16.95 | 3.13B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Neutral |
| Mar-03-25 | Initiated | Jefferies | Hold |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Immunovant Executives Sell Shares to Cover Tax Obligations - TradingView
Can Immunovant Inc. stock recover from recent declineHigh-profit stock alerts - jammulinksnews.com
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN
Is Immunovant Inc. a good long term investmentExceptional gains - PrintWeekIndia
What drives Immunovant Inc. stock priceHigh-profit stock alerts - Autocar Professional
What analysts say about Immunovant Inc. stockTremendous wealth creation - Autocar Professional
Why Immunovant Inc. stock attracts strong analyst attentionFree Daily Stock Market Updates - Newser
How high can Immunovant Inc. stock price go in 2025Free Smart Trading Workshop - jammulinksnews.com
Immunovant, Inc. (NASDAQ:IMVT) Shares Purchased by Arizona State Retirement System - Defense World
Immunovant Inc. Stock Analysis and ForecastRecord-setting profit potential - jammulinksnews.com
Teacher Retirement System of Texas Buys 2,919 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
why immunovant inc. stock attracts strong analyst attentionFree Access to Community - Newser
September 19th Options Now Available For Immunovant (IMVT) - Nasdaq
(IMVT) Trading Advice - news.stocktradersdaily.com
All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy - Yahoo Finance
Goldman Sachs Resumes Coverage of Immunovant (IMVT) with a Hold Rating - MSN
Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High? - Yahoo Finance
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
What makes Immunovant Inc. stock price move sharplyShort Squeeze Radar - Newser
How Immunovant Inc. stock performs during market volatilityFree Trading Strategy Suggestions - Newser
Principal Financial Group Inc. Sells 31,255 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
The Goldman Sachs Group Upgrades Immunovant (NASDAQ:IMVT) to Hold - Defense World
Immunovant (IMVT) chief technology officer Stout sells $26k in stock - Investing.com Australia
Goldman Sachs resumes Immunovant stock coverage with Neutral rating By Investing.com - Investing.com Canada
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by Mirae Asset Global Investments Co. Ltd. - Defense World
(IMVT) Technical Data - news.stocktradersdaily.com
How to Take Advantage of moves in (IMVT) - news.stocktradersdaily.com
Immunovant (NASDAQ:IMVT) Stock Updated Nasdaq Composite - Kalkine Media
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):